What is H-CYTE?
H-CYTE operates as a multifaceted medical technology enterprise dedicated to enhancing patient quality of life through innovative clinical interventions. The company's operational framework is anchored by two primary pillars: the development of proprietary medical devices and the management of specialized biomedical services. Its flagship innovation, the DenerveX System, addresses the clinical needs of patients suffering from facet joint syndrome by providing durable pain relief. Simultaneously, the company oversees the Lung Health Institute, a prominent entity in the regenerative medicine sector. This division focuses on advanced cellular therapies aimed at treating chronic obstructive pulmonary disease (COPD) and other debilitating respiratory conditions. By integrating device-based pain management with regenerative biologics, H-CYTE maintains a robust presence in the high-growth healthcare sector.
How much funding has H-CYTE raised?
H-CYTE has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in H-CYTE
PPP
Public-Private Partnership
What's next for H-CYTE?
Following this strategic capital injection, H-CYTE is positioned to accelerate its clinical development pipeline and expand its therapeutic reach. A primary focus for the organization involves the advancement of its biologics division, LungCYTE, particularly regarding the submission of Investigational New Drug (IND) applications to the FDA. This regulatory milestone is critical for the commercialization of proprietary biologics designed to address unmet needs in COPD treatment. As the company transitions through this late-stage growth phase, management is expected to prioritize the scaling of its regenerative medicine services and the broader market adoption of the DenerveX System. The infusion of capital provides the necessary liquidity to navigate complex clinical trials and sustain long-term operational excellence in the competitive medical technology landscape.
See full H-CYTE company page
